Get the Stockscreener App
25.29
0.43%
0.085
Bridgebio Pharma Inc stock is traded at $25.29, with a volume of 431.21K.
It is up +0.43% in the last 24 hours and up +0.31% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$25.20
Open:
$25.01
24h Volume:
431.21K
Relative Volume:
0.23
Market Cap:
$4.73B
Revenue:
$219.12M
Net Income/Loss:
$-453.82M
P/E Ratio:
-6.4833
EPS:
-3.9
Net Cash Flow:
$-419.68M
1W Performance:
+3.30%
1M Performance:
+0.31%
6M Performance:
-9.06%
1Y Performance:
-12.21%
1-Day Range:
$24.46
$25.47
1-Week Range:
$23.35
$25.81
52-Week Range:
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Dives on Revealing Case Study - Baystreet.ca
BridgeBio Announces Publication of Case Study Exploring - GlobeNewswire
BridgeBio's Portfolio Theory Innovation Reshapes Drug Development Strategy | BBIO Stock News - StockTitan
Achondroplasia Market Forecasted to Surge in Coming Years, - openPR
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Increased by Emerald Advisers LLC - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 8.3%Still a Buy? - MarketBeat
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance Australia
(BBIO) Proactive Strategies - Stock Traders Daily
Seven PDUFA dates on FDA’s November calendar - BioCentury
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Yahoo Finance
Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat
Gene therapy shows promise in Canavan disease trial By Investing.com - Investing.com Australia
Citi reiterates Buy rating on BridgeBio shares, cites clinical results By Investing.com - Investing.com Canada
Gene therapy shows promise in Canavan disease trial - Investing.com
BridgeBio Shares Positive Data from High Dose Cohort of - GlobeNewswire
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene - The Bakersfield Californian
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - StockTitan
Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Objective long/short (BBIO) Report - Stock Traders Daily
Scotiabank Initiates Coverage of BridgeBio Pharma (BBIO) with Sector Outperform Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Price Target Cut to $46.00 by Analysts at Leerink Partners - MarketBeat
Equities Analysts Offer Predictions for BridgeBio Pharma, Inc.'s Q3 2024 Earnings (NASDAQ:BBIO) - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for BBIO Earnings - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at Scotiabank - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 4.7%Time to Buy? - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market Emerging - openPR
BridgeBio Pharma (NASDAQ:BBIO) Shares Down 4.6%Here's What Happened - MarketBeat
When the Price of (BBIO) Talks, People Listen - Stock Traders Daily
Marshall Wace LLP Invests $781,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
3 Top Stocks That Could Still Rocket Higher in 2024 - AOL
Algert Global LLC Has $1.42 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Oppenheimer Initiates Coverage of BridgeBio Pharma (BBIO) with Perform Recommendation - Nasdaq
BridgeBio granted Perform rating at Oppenheimer on market challenges (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Oppenheimer - MarketBeat
BridgeBio to Present Outcomes Data Through 42 Months from - GlobeNewswire
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions - StockTitan
Ghisallo Capital Management LLC Sells 33,750 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Cut by Ghisallo Capital Management LLC - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Quarry LP - Defense World
5 FDA decisions to watch in the fourth quarter - Yahoo Finance
Capital Impact Advisors LLC Reduces Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
BridgeBio completes enrollment for potential LGMD2I therapy By Investing.com - Investing.com South Africa
BridgeBio shares maintain Market Perform rating from BMO By Investing.com - Investing.com Canada
Piper Sandler keeps Overweight rating on BridgeBio Pharma stock By Investing.com - Investing.com Canada
BridgeBio shares hold ratings with positive study data By Investing.com - Investing.com Canada
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease - AOL
Early-Stage Biotech BridgeBio's Acoramidis Drives Valuation for Long-Term Investors - Morningstar
Transthyretin Amyloid Cardiomyopathy Market Size, Share, - openPR
BridgeBio Pharma's (BBIO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):